[Dmt¹]DALDA is Highly Selective and Potent at Opioid Receptors, but is not Cross-Tolerant with Systemic Morphine
Authors: Riba, P.; Ben, Y.; Nguyen, T.M.; Furst, S.; Peter; Schiller, W.; Lee, N.M.
Source: Current Medicinal Chemistry, Volume 9, Number 1, January 2002 , pp. 31-39(9)
Publisher: Bentham Science Publishers
Abstract:The clinical effectiveness of morphine is limited by several side effects, including the development of tolerance and dependence. Most of these side effects are believed to be mediated by central opioid receptors therefore, hydrophilic opioids, which don't cross the blood-brain barrier, may have advantages over morphine in some clinical applications. We recently synthesized several analogues of DALDA (Tyr-D-Arg-Phe-Lys-NH2), a highly hydrophilic peptide derived from the endogenous opioid peptide dermorphin; all of them, particularly [Dmt¹] DALDA (Dmt - 2',6'-dimethyl tyrosine), had high potency and selectivity at receptors, the target of morphine, in activity assays.
Here we report the pharmacological characterization of [Dmt¹] DALDA in the whole animal. [Dmt¹]DALDA was 40 times more potent than morphine in inducing antinociception in mice when both drugs were given s.c., and 6-14 times more potent than DAMGO, a selective agonist, when both drugs were given it. However, [Dmt¹]DALDA showed poor cross-tolerance to morphine; thus chronic morphine treatment of animals increased the antinociceptive AD50 of systemic [Dmt1]DALDA two fold or less, as compared to an 8-9-fold increase for morphine and a 4-5-fold increase for DAMGO. The antinociceptive activity of [Dmt¹]DALDA (i.t) was blocked by CTAP, a selective antagonist, but not by TIPPΨ, a selective antagonist, nor by nor-BNI, a selective antagonist. [Dmt¹]DALDA-induced antinociception was also blocked by naloxone methiodide, an antagonist that does not cross the blood-brain barrier, when agonist and antagonist were given i.t. or i.c.v., but not when they were given s.c. We conclude that [Dmt¹] DALDA is a highly potent analgesic acting at receptors. Though it appears to penetrate the blood-brain barrier, it exhibits low cross-tolerance to morphine, suggesting that it may have advantages over the latter in certain clinical applications.
Document Type: Review Article
Publication date: 2002-01-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.